Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mount Sinai Medical Center (NY)

www.mountsinai.org

Latest From Organon NV

Tech Transfer Roundup: Boehringer Fits Deal Structure To Partner's Expertise

Boehringer Ingelheim's Paola Casarosa explains that when her company partners with academia, it looks for the best way to mine that level of expertise rather than trying to fit the collaboration to a preferred deal model. Plus, our roundup includes three cancer-related deals and one for dry eye disease.

Deals StartUps and SMEs

Appointments: Promethera, HealthTell, Baxter, Alzheon, Gilead, Arena and Ligand

This week's appointment roundup includes senior appointments by Promethera, HealthTell, Alzheon and Gilead Nordic with Baxter International, Therachon and Arena Pharmaceuticals making board appointments.

Appointments

Distortion And Inflation In Measuring Pharma M&A

Five companies in big pharma’s top 20 have come through mergers in the past 10 years or so that changed them significantly. As measured by standard financial performance parameters, the processes at Takeda and Teva (and to some extent, at Allergan) seem relatively smooth and productive. Those at Pfizer and Merck don’t. But it depends on how you look at the numbers.

Deals Business Strategies

Putting Substance In “Substantial Evidence”: FDA Standards Take Center Stage In Rejection of Gepirone

Fabre-Kramer is asking FDA to reconsider its depression drug gepirone, nearly a decade after the agency rejected the application for the third time. The sponsor's case appears to be based on the hope that today's FDA will take a different view than the 2007 version of the agency.

BioPharmaceutical Advisory Committees
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register